Enobia lassos $40M in private placement for bone-targeting ERT
This article was originally published in Scrip
Executive Summary
Canadian biotech Enobia Pharma raised $40 million through a private placement of 13.7 million shares of its common stock to new pharmaceutical and financial investors.